Profile data is unavailable for this security.
About the company
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
- Revenue in USD (TTM)277.00k
- Net income in USD-33.80m
- Incorporated2020
- Employees83.00
- LocationATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
- Phone+49 8 921539035
- Fax+49 89 215390351
- Websitehttps://atai.life/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rezolute Inc | 0.00 | -58.21m | 240.47m | 51.00 | -- | 2.65 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
2Seventy Bio Inc | 71.20m | -223.22m | 246.23m | 274.00 | -- | 1.19 | -- | 3.46 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Aldeyra Therapeutics Inc | 0.00 | -30.01m | 246.57m | 10.00 | -- | 2.17 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
Zura Bio Ltd | 0.00 | -60.18m | 247.97m | 14.00 | -- | 2.78 | -- | -- | -1.63 | -1.63 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -86.77 | -- | -127.21 | -- | -- | -- | -- | -- | -- | -- | 0.021 | -- | -- | -- | -2,050.99 | -- | -- | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 253.36m | 135.00 | -- | 9.48 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
Nektar Therapeutics | 90.17m | -175.84m | 253.40m | 137.00 | -- | 2.00 | -- | 2.81 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -25.20 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Mersana Therapeutics Inc | 38.30m | -134.81m | 256.96m | 123.00 | -- | 9.18 | -- | 6.71 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Tectonic Therapeutic Inc | 0.00 | 30.31m | 259.91m | 13.00 | 2.13 | 0.7426 | 8.50 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Codexis Inc | 74.23m | -65.13m | 261.06m | 174.00 | -- | 3.29 | -- | 3.52 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
AVITA Medical Inc | 50.70m | -44.82m | 261.35m | 207.00 | -- | 8.02 | -- | 5.16 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
ATAI Life Sciences NV | 277.00k | -33.80m | 266.18m | 83.00 | -- | 1.19 | -- | 960.92 | -0.24 | -0.24 | 0.0017 | 1.34 | 0.001 | -- | 0.0429 | 3,337.35 | -11.88 | -- | -12.80 | -- | -- | -- | -11,790.25 | -- | -- | -104.16 | 0.0809 | -- | 34.76 | -- | 73.60 | -- | -- | -- |
Acrivon Therapeutics Inc | 0.00 | -64.12m | 273.57m | 58.00 | -- | 1.86 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Artiva Biotherapeutics Inc | -100.00bn | -100.00bn | 279.38m | 25.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -351.24 | -- | -- | -- |
Monte Rosa Therapeutics Inc | 1.06m | -135.28m | 284.12m | 133.00 | -- | 1.54 | -- | 267.03 | -2.53 | -2.53 | 0.0197 | 3.04 | 0.0037 | -- | 0.768 | 8,000.00 | -46.99 | -- | -52.64 | -- | -- | -- | -12,714.47 | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
Inovio Pharmaceuticals Inc | 717.07k | -124.94m | 293.31m | 122.00 | -- | 2.80 | -- | 409.04 | -5.54 | -5.54 | 0.0317 | 4.04 | 0.0036 | -- | 0.5465 | 5,877.62 | -63.15 | -59.52 | -78.79 | -71.29 | -- | -- | -17,423.39 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
Holder | Shares | % Held |
---|---|---|
Millennium Management LLCas of 31 Mar 2024 | 2.22m | 1.32% |
Morgan Stanley Investment Management, Inc.as of 31 Mar 2024 | 1.69m | 1.01% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 895.19k | 0.54% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 880.30k | 0.53% |
Marshall Wace LLPas of 31 Mar 2024 | 793.84k | 0.47% |
Brown University Investment Officeas of 31 Mar 2024 | 718.50k | 0.43% |
BlackRock Advisors (UK) Ltd.as of 31 Mar 2024 | 518.17k | 0.31% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 413.78k | 0.25% |
Two Sigma Investments LPas of 31 Mar 2024 | 400.99k | 0.24% |
Fiduciary Trust International LLCas of 31 Mar 2024 | 356.36k | 0.21% |